Cargando…

Treatment of immunothrombosis dysregulation: high-dose corticosteroids is not the good option

Detalles Bibliográficos
Autores principales:	Helms, Julie, Poissy, Julien, Dequin, Pierre-François, Timsit, Jean-François
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307762/ https://www.ncbi.nlm.nih.gov/pubmed/37380873 http://dx.doi.org/10.1186/s13613-023-01158-1

Ejemplares similares

Dysregulated Hemostasis and Immunothrombosis in Cerebral Cavernous Malformations
por: Globisch, Maria Ascencion, et al.
Publicado: (2022)

Epidural Tramadol, is it a Good Option for Cesarean Section?
por: Carvalho, Luciana de Souza Cota
Publicado: (2011)

Comment on Comparison of the Outcome of Low Dose and High-Dose Corticosteroid in the Treatment of Idiopathic Granulomatous Mastitis
por: Akbulut, Sami, et al.
Publicado: (2020)

Good efficacy achieved by telitacicept, corticosteroids and immunosuppressants in the treatment of SLE combined with MOG-AD
por: Tian, Mengxue, et al.
Publicado: (2023)

Endotracheal Intubation Without Neuromuscular Blocking Agents: Is It a Good and Safe Option?
por: Akan, Mert, et al.
Publicado: (2012)

Dysregulated miRNAs network in the critical COVID-19: An important clue for uncontrolled immunothrombosis/thromboinflammation
por: Mortazavi-Jahromi, Seyed Shahabeddin, et al.
Publicado: (2022)

Early short-course corticosteroids and furosemide combination to treat non-critically ill COVID-19 patients: An observational cohort study
por: Kevorkian, Jean-Philippe, et al.
Publicado: (2021)

Immunothrombosis in severe COVID-19
por: Nakazawa, Daigo, et al.
Publicado: (2020)

Intracellular communication and immunothrombosis in sepsis
por: Iba, Toshiaki, et al.
Publicado: (2022)

Endothelial dysfunction and immunothrombosis in sepsis
por: Maneta, Eleni, et al.
Publicado: (2023)

Critically ill SARS-CoV-2-infected patients are not stratified as sepsis by the qSOFA
por: Ferreira, Marion, et al.
Publicado: (2020)

Conducting trials on corticosteroid dosing for respiratory failure in the last paradise
por: Shime, Nobuaki
Publicado: (2018)

Fatal Measles without Rash in Immunocompetent Adult, France
por: Lupo, Julien, et al.
Publicado: (2012)

Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome
por: Knight, Jason S., et al.
Publicado: (2022)

COVID-19: Lung-Centric Immunothrombosis
por: Kvietys, Peter R., et al.
Publicado: (2021)

Chemokines, molecular drivers of thromboinflammation and immunothrombosis
por: Leberzammer, Julian, et al.
Publicado: (2023)

Intensified thromboprophylaxis in COVID-19 critically ill patients: Is it enough?
por: de Montmollin, Etienne, et al.
Publicado: (2021)

Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19
por: Fang, Xiaowei, et al.
Publicado: (2020)

Steroids: A Therapeutic Option for COVID-19 Pneumonia Patients With ESRD?
por: Delafosse, Marion, et al.
Publicado: (2020)

Hydroxychloroquine at usual doses as an option for coronavirus disease 2019 treatment
por: Carbillon, Lionel, et al.
Publicado: (2021)

Decreasing humoral response among healthcare workers up to 4 months after two doses of BNT162b2 vaccine
por: Ferré, Valentine Marie, et al.
Publicado: (2022)

Re: Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19
por: Jung, Jiwon, et al.
Publicado: (2020)

The Emerging Role of NETs in Venous Thrombosis and Immunothrombosis
por: Kimball, Andrew S., et al.
Publicado: (2016)

Immunothrombosis in Acute Respiratory Dysfunction of COVID-19
por: Fang, Xiang-Zhi, et al.
Publicado: (2021)

Mechanisms of Immunothrombosis by SARS-CoV-2
por: Hernández-Huerta, María Teresa, et al.
Publicado: (2021)

COVID-19 and immunothrombosis: Pathophysiology and therapeutic implications
por: Lim, Ming Sheng, et al.
Publicado: (2021)

Evolutionary Insight into Immunothrombosis as a Healing Mechanism
por: Anitua, Eduardo, et al.
Publicado: (2022)

C-reactive protein, immunothrombosis and venous thromboembolism
por: Dix, Caroline, et al.
Publicado: (2022)

Immunothrombosis and the Role of Platelets in Venous Thromboembolic Diseases
por: Heestermans, Marco, et al.
Publicado: (2022)

Immunothrombosis: Molecular Aspects and New Therapeutic Perspectives
por: Marcos-Jubilar, María, et al.
Publicado: (2023)

Immunothrombosis and vascular heterogeneity in cerebral cavernous malformation
por: Globisch, Maria A., et al.
Publicado: (2022)

Reply to “Early resolution of subretinal fluid without high-dose corticosteroids in a pregnant patient with Vogt-Koyanagi Harada disease” by Sugita et al.
por: Babu, Kalpana, et al.
Publicado: (2016)

Topical corticosteroid therapy: a treatment option for nevus lipomatosus cutaneous superficialis?
por: Castagna, Rafaella Daboit, et al.
Publicado: (2018)

Intraocular pressure: Focus on corticosteroids
por: Shukla, Dhananjay
Publicado: (2021)

Preventing the development of severe COVID-19 by modifying immunothrombosis
por: Morris, Gerwyn, et al.
Publicado: (2021)

Extracellular DNA—A Danger Signal Triggering Immunothrombosis
por: Shi, Chongxu, et al.
Publicado: (2020)

COVID-19-Associated Coagulopathy: An Exacerbated Immunothrombosis Response
por: Jayarangaiah, Apoorva, et al.
Publicado: (2020)

Immunothrombosis in COVID-19: Implications of Neutrophil Extracellular Traps
por: Bautista-Becerril, Brandon, et al.
Publicado: (2021)

The Good, the Bad, and the Hoax: When Publication Instantaneously Impacts Treatment Strategies for COVID-19
por: Danion, François, et al.
Publicado: (2020)

Corticosteroids and rehabilitation in COVID-19 survivors
por: Lal, Amos, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_27ahs2gta817g47dtrsh0gd5eg